GSK new HIV two-drug injection meets main goal in late-stage study

By | August 22, 2019

FILE PHOTO: The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. REUTERS/Loriene Perera/File Photo GLOBAL BUSINESS WEEK AHEAD

(Reuters) – British drugmaker GlaxoSmithKline Plc said on Thursday its long-lasting two-drug regimen to treat HIV met the main goal of a late-stage study.

The needle-based HIV regimen of its drug cabotegravir and Janssen’s treatment rilpivirine, given every two months, was as effective as a monthly dose of the two drugs in maintaining viral suppression at 48 weeks, ViiV Healthcare, the London-listed company’s HIV unit said.

Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur

Reuters: Health News